BIA-Brukerstyrt innovasjonsarena

Innovation on Signalling Disruptors - Development of drugs eliminating cAMP action in infectious disease (HIV/AIDS) and cancer

Compartmentalised cAMP-dependent signalling is involved in development of a number of diseases including HIV/AIDS, certain types of cancer, and other types of immunodeficiencies which affect several million citizens both in industrialised and developing c ountries each year. No organised approach...

Awarded: NOK 5.9 mill.

Project Period: 2007-2009

Location: Oslo

FUGE-Funksjonell genomforskn.i Norg

Development of immunostimulatory therapy disrupting the hyperactivated cAMP signalling pathway in HIV immunodeficiency

LAURAS is developing immunostimulatory drugs that will reverse the immunodeficiency in HIV and other immunodeficiencies. Such treatment is called for since the present antiretroviral treatment (HAART) does not offer cure for the disease, is associated wit h resistance and has significant side eff...

Awarded: NOK 4.7 mill.

Project Period: 2005-2007

Location: Oslo

PROSBIO-Prosess- og biomedisinsk industri

Immunstimulerende behandling ved HIV infeksjon og andre immunsviktsykdommer

Lauras AS har til formål å frambringe et produkt som reverserer immunsvikt hos HIV-pasienter og stimulerer immunsystemet. Det er forventninger om at slik behandling kombinert med terapi rettet mot viruset og terapeutisk vaksinering vil bidra til at kroppe ns eget immunforsvar kvitter seg helt med...

Awarded: NOK 5.6 mill.

Project Period: 2002-2004

Location: Oslo